Literature DB >> 1423246

Adenoma-derived antibody, Adnab-9 recognizes a membrane-bound glycoprotein in colonic tissue and effluent material from patients with colorectal neoplasia.

M Tobi1, B Maliakkal, I Zitron, M Alousi, R Goo, L Nochomovitz, G Luk.   

Abstract

The binding in pre-colonoscopic effluent of Adnab-9, a monoclonal antibody raised against colonic adenomas, was evaluated for specificity in the diagnosis of colorectal cancer. A heterogeneous group of 58 patients was evaluated by ELISA. Effluent samples and tissue extracts were subjected to Western blotting or ELISA to confirm specificity. Immunohistochemistry was performed on the cancer tissue sections. The proportion of positive effluent binding was higher in the cancer when compared to the normal group (P = 0.036). A dominant 87 M(r) band was found in adenoma extracts and some effluent samples. Adnab-9 binding in effluent samples predominated in membrane-bound fractions. Immunohistochemistry showed no specific staining in the cancer cells. The antigen recognised is a glycoprotein shown by effects of N-glycanase digestion and not cross-reactive with carcinoembryonic antigen. Non-gastro-intestinal tissue extracts did not bind Adnab-9. The major 87 M(r) adenoma-derived antigen may be found in effluent material, particularly in the membrane-bound fraction.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1423246     DOI: 10.1016/0304-3835(92)90009-k

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  8 in total

1.  Colorectal cancer in the cotton top tamarin (Saguinus oedipus): how do they evade liver metastasis?

Authors:  Martin Tobi; Mijin Kim; Regis Zimmer; James Hatfield; Michael Kam; Nabiha Khoury; Angela Carville; Michael J Lawson; William P Schiemann; Peter Thomas
Journal:  Dig Dis Sci       Date:  2010-07-20       Impact factor: 3.199

Review 2.  Avoiding hepatic metastasis naturally: Lessons from the cotton top tamarin (Saguinus oedipus).

Authors:  Martin Tobi; Peter Thomas; Daniel Ezekwudo
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

3.  Differential labeling by monoclonal antibodies Adnab-9 and anti-alpha-defensin 5 based on the distribution and adenomatous tissue content of colonic polyps.

Authors:  Nadeem Ullah; Kashif Qureshi; Violeta Yordanova; James Hatfield; Paula Sochacki; Michael Lawson; Martin Tobi
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

4.  Gastrointestinal tract antigenic profile of cotton-top tamarin, Saguinus oedipus, is similar to that of humans with inflammatory bowel disease.

Authors:  M Tobi; S Chintalapani; K Kithier; N Clapp
Journal:  Dig Dis Sci       Date:  2000-12       Impact factor: 3.199

5.  Colorectal cancer risk: the impact of evidence of a field effect of carcinogenesis on blinded diagnosis using an anti-adenoma antibody test performed on colonoscopic effluent.

Authors:  Martin Tobi; Shivkumar Prabhu; Rhonda E Gage; Tashia Orr; Michael J Lawson
Journal:  Dig Dis Sci       Date:  2002-02       Impact factor: 3.199

6.  Correlation of Ki-67, p53, and Adnab-9 immunohistochemical staining and ploidy with clinical and histopathologic features of severely dysplastic colorectal adenomas.

Authors:  Rafiq A Sheikh; Byung Hee Min; Shagufta Yasmeen; Raymond Teplitz; Henry Tesluk; Boris Henry Ruebner; Martin Tobi; James Hatfield; Suzanne Fligiel; Michael J Lawson
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

Review 7.  Rectal effluent as a research tool.

Authors:  Jana M Rocker; Jack A DiPalma; Lewis K Pannell
Journal:  Dig Dis Sci       Date:  2014-09-02       Impact factor: 3.199

8.  The use of early and midpoint adenoma-carcinoma sequence biomarkers in prediction of neoplastic progression in patients with a history of colorectal neoplasia.

Authors:  Hassan Albataineh; Violeta Yordanova; Jessica Bowman; Weili Zhou; James Hatfield; Michael J Lawson; Paula Sochacki; Martin Tobi
Journal:  Dig Dis Sci       Date:  2006-11-01       Impact factor: 3.487

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.